Siddiqui MR, Edmunds WJ.. Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic. Emerg Infect Dis. 2008 Feb;14(2):267-74.
A decision analytical model was developed to investigate the cost-effectiveness of stockpiling antiviral (AV) drugs for a potential influenza pandemic in the United Kingdom and the possible role of near-patient testing in conserving AV drug stocks. Under base-case assumptions (including a fixed stockpile that was smaller than the clinical attack rate), the treat-only option (treating all symptomatic patients with AV drugs) would be considered cost-effective ( pound1,900- pound13,700 per quality-adjusted life year [QALY] gained, depending on the fatality scenario), compared with no intervention (nonintervention but management of cases as they arise). The test-treat option (testing all symptomatic patients but treating those with positive tests results only) would result in moderate gains in QALYs over the treat-only option but at relatively large additional costs. Stockpiling sufficient AV drugs (but not near-patient tests) to treat all patients with clinical cases would be cost-effective, provided AV drugs are effective at preventing deaths from pandemic influenza.
See Also:
Latest articles in those days:
- [preprint] Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle 17 hours ago
- Modelling the transmission dynamics of H9N2 avian influenza viruses in a live bird market 17 hours ago
- CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age 3 days ago
- Surveillance for highly pathogenic avian influenza A (H5N1) in a raptor rehabilitation center-2022 3 days ago
- [preprint]Detection of hemagglutinin H5 influenza A virus sequence in municipal wastewater solids at wastewater treatment plants with increases in influenza A in spring, 2024 3 days ago
[Go Top] [Close Window]